Adjuvant bevacizumab not recommended for melanoma, HER2-negative breast cancer

Source: Medwire News, September 2018

medwireNews: The AVAST-M and E5103 trial results rule out the use of bevacizumab in the adjuvant setting in high-risk patients with cutaneous melanoma and HER2-negative breast cancer, respectively.

Treatment with the VEGF inhibitor did not lead to an overall survival (OS) benefit in either trial, and neither was invasive disease-free survival (IDFS) improved in the breast cancer study.

In line with an interim analysis of the AVAST-M trial, bevacizumab continued to impart a disease-free survival benefit in patients with melanoma, but given the OS findings, the researchers say that “bevacizumab cannot be recommended as a standard adjuvant therapy after resection of melanoma at high risk of recurrence.”